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A 44-year-old white woman was admitted to The New York Hospital for
a living-donor renal transplant from her husband. One and one-half years
prior to admission for transplantation, she was found to have advanced
renal failure; renal biopsy at that time revealed crescentic glomerulone-
phritis. The patient was started on maintenance hemodialysis one year
prior to admission for transplantation.
Pre-transplantation serology studies were negative for hepatitis B and
hepatitis C virus. The recipient and donor were cytomegalovirus positive.
The HLA type of the recipient was A2, All, B51, B52, and DR2 and 4; the
HLA type of the donor was A2, A24, B51, B62, and DR1 and 5. The
recipient was preconditioned with a regimen of donor-specific transfusions
and cyclosporine. Donor-specific T- and B-cell crossmatches, including the
flow cytometry crossmatch, were negative, and the patient underwent
renal transplantation from her spousal donor. The immunosuppressive
regimen comprised cyclosporine (10 mg/kg/day, in two divided doses),
azathioprine, and corticosteroids.
The renal transplant functioned immediately. The patient's serum
creatinine decreased from a pretransplant value of 14.6 nig/dI to 1.0 mg/dl
by the second postoperative day and remained at that level until day 5 post
transplantation. On postoperative day 6, her serum creatinine increased to
2.8 mg/dl. A renal scan showed decreased uptake, and the renal sonogram
did not reveal an obstruction. A diagnosis of acute rejection was made,
and the patient received a course of steroid pulse therapy (250 mg
intravenously, twice daily for 3 days). Her serum creatinine level peaked at
5.4 mg/dl on day 9 post transplantation. The patient responded to pulse
therapy, and the serum creatinine level declined until day 15. A percuta-
neous core needle biopsy disclosed changes consistent with acute cellular
rejection. The renal biopsy material was processed for mRNA phenotyp-
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ing by reverse-transcriptase polymerase chain reaction (RT-PCR). Fol-
lowing a second course of steroid pulse therapy, the patient's serum
creatinine declined to 1.5 mg/dl, and she was discharged from the hospital
on day 20 post transplantation. Her medications at that time included the
following immonosuppressants: cyclosporine, 250 mg orally, twice daily;
azathioprine, 150 mg orally each day; and prednisone, 30 mg orally twice
daily. Her whole-blood cyclosporine level (determined with the monoclo-
nal antibody specific for the parent compound) ranged from 90 ng/ml to
360 ng/ml during the transplant hospitalization. The patient is being
followed in the transplant clinic, and her serum creatinine values were 1.1,
1.3, 1.5 and 1.6 mg/dl four, three, two, and one year ago, respectively.
Discussion
DR. MANIKKAM SUTHANTHIRAN (Director of Research, The Ro-
gosin Institute; and Chief Department of Transplantation Medicine
and Extracorporeal Therapy, The New York Hospital-Cornell Med-
ical Center, New York, New York, U.S.A.): Renal transplantation is
the preferred treatment for most patients afflicted with end-stage
renal disease [1, 2]. A great disparity exists, however, between the
demand for and the availability of organs for transplantation [3].
Thus, in addition to living-related and cadaveric grafts, emotion-
ally related living-donor renal transplantation is performed in
many transplant centers. Spousal donor grafts, like the one used in
the case under discussion, represent a vital resource and exhibit
high graft survival rates [4].
The patient, recipient of a two DR antigen-mismatched kidney,
experienced biopsy-proven acute rejection, the most frequent
serious complication following renal transplantation. The inci-
dence of rejection has been correlated with the degree of HLA
mismatching; the incidence is 28% with two DR antigen-mis-
matched kidneys, 25% with one, and 19% with zero DR antigen
mismatches (P < 0.001, each comparison) [5].
The occurrence of even one reversible rejection is associated
with inferior graft survival rates; in the UNOS Scientific Renal
Transplant Registry, first transplant recipients who were rejec-
tion-free at discharge had an 86% one-year graft survival rate
compared to 67% for those with one or more rejection episodes
(P < 0.001) [5]. A long-term adverse consequence also is reported
following acute rejection. The estimated half-life (time taken for
50% of the grafts functioning at one year to fail) for patients
without acute rejection was 8.6 years, and 7.4 years for the
recipients with one or more rejections [5]. Acute rejection is also
considered to be a significant risk factor for the subsequent
development of chronic rejection [6]. The progressive decline in
the renal function observed in today's patient is most probably
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due to the development of chronic rejection, a relentlessly pro-
gressive process and a major cause of long-term graft dysfunction
and ultimate failure [7].
The unfavorable impact of the rejection process also is magni-
fied by the fact that the use of high-dose anti-rejection therapy,
superimposed on maintenance immunosuppression, is a major
cause of the morbidity and mortality associated with transplanta-
tion [8]. Moreover, the immunization against "public" HLA-
specificities resulting from a rejected graft renders this patient
population difficult to transplant again [9, 10]. The return of the
immunized recipient with a failed graft to the pooi of patients
awaiting transplantation also intensifies the perennial problem of
organ shortage [3].
Definition and problems in diagnosis
Renal graft rejection is defined as renal functional and struc-
tural deterioration due to an active immune response expressed
by the recipient, and independent of non-immunologic causes of
renal dysfunction [11, 12]. The diagnosis is usually made upon the
development of graft dysfunction (for example, an increase in the
concentration of serum creatinine) and with morphologic evi-
dence of graft injury in areas of the graft also manifesting
mononuclear cell infiltration [13].
Two caveats apply, however, to the use of abnormal renal
function as an indicator of the rejection process: first, deteriora-
tion in renal function is not always available as a clinical clue for
diagnosing rejection, since many of the cadaveric renal grafts
suffer from acute (reversible) renal failure in the immediate
post-transplantation period because of injury from harvesting and
ex-vivo preservation procedures. Second, even when the graft
functions immediately, graft dysfunction can develop due to a
non-immunologic cause. For example, cyclosporine (CsA) neph-
rotoxicity, a complication that is not readily identified solely on
the basis of plasma/blood concentrations of CsA [14], is a
common complication following transplantation. The clinical im-
portance of distinguishing rejection from CsA nephrotoxicity
cannot be overemphasized because the therapeutic strategies are
diametrically opposite: an increase of immunosuppressants for
rejection, and a reduction of CsA dosage for nephrotoxicity [12,
141.
Additional problems surround the current methods of diagnosis
and management of renal allograft rejection: (1) the "morning
after pill" approach: a given rejection episode is not anticipated
and treatment is initiated after the immune assault mechanisms
have engendered functional deterioration of the allograft. This
after-the-fact strategy also is ineffective in preventing the late
occurrence of chronic rejection; (2) the "one size fits all" ap-
proach: anti-rejection treatment protocols generally utilize a
standard dosage of steroids or monoclonal antibodies (mAb) and
treatment is not individualized on a rational basis; (3) the need to
perform invasive core needle biopsies to definitely establish the
diagnosis; (4) the lack of reliable prognostic histologic features
regarding reversibility of rejection or responsiveness to therapy;
and (5) the lack of a molecular mechanism-based treatment.
The anti-allografi response
In an effort to resolve the existing problems of allograft
rejection, the immune and molecular mechanisms of acute human
renal graft rejection are being explored in several laboratories. I
will discuss some of the new knowledge gained regarding mech-
anisms of activation of T-lymphocytes—the primary cells respon-
sible for graft rejection—and then offer an overview of immune
and molecular mechanisms of the anti-allograft response.
T-cell stimulation. T-cell activation begins following T-cell rec-
ognition of intracellularly processed fragments of foreign proteins
embedded within the groove of the major histocompatibility
complex proteins (MHC) expressed on the surface of antigen-
presenting cells (APCs) [15, 16]. T-cells of the recipient can
directly recognize the allograft, that is, donor antigen(s) presented
on the surface of donor APCs (direct recognition), and also when
the donor antigen is processed and presented by the recipient's
APCs (indirect recognition) [17]. The relative contributions of
direct and indirect recognition to the generation of graft destruc-
tive or adaptive immunity remain unresolved.
The T-cell antigen receptor (TCR)/CD3 complex is comprised
of clonally variant TCR c43 peptide chains that recognize the
antigenic peptide in the context of MHC proteins and clonally
invariant CD3 chains, y, , €, and that initiate intracellular
signals originating from antigenic recognition [18, 19]. The CD4
and CD8 proteins, expressed on reciprocal T-cell subsets, bind to
non-polymorphic domains of HLA class 11 (DR, DQ) and class I
(A, B, C) molecules, respectively [20]. Antigenic recognition
stimulates a redistribution of cell-surface proteins and co-cluster-
ing of the TCR/CD3 complex with the CD4 or CD8 antigens. This
multimeric complex includes additional signaling molecules, CD2
and CDS proteins, and functions as a unit in initiating T-cell
activation [21—23].
Signal transduction. The TCRICD3 complex is physically asso-
ciated with two intracellular protein tyrosine kinases of the src
family, p59' and ZAP 70, and the cytoplasmic domains of the
CD4 and CD8 antigens with an additional member of the src
family of tyrosine kinases, p56' [241. Following antigenic engage-
ment of the TCR/CD3 complex, intracellular tyrosine and/or
serine residues of CD3 €, y, and chains are phosphoiylated. The
CD45 protein, a tyrosine phosphatase, contributes to the activa-
tion process by dephosphorylating an auto-inhibitory site, tyrosine
residue 505, of the protein tyrosine kinase p56'.
Tyrosine phosphorylatiori is an important signal transduction
event because tyrosine phosphorylation of the phospholipase Cy1
activates this co-enzyme and initiates a cascade of events: enzy-
matic hydrolysis of phosphatidylinositol 4,5-biphosphate (PIP2)
and generation of two intracellular messengers, inositol 1, 4,5
triphosphate (1P3) and diacylglycerol [25]. In turn, 1P3 mobilizes
ionized calcium from bound intracellular stores, while diacylglyc-
erol, in the presence of increased cytosolic free Ca2, binds to and
translocates protein kinase C (PKC)—a phospholipid/Ca2 -sen-
sitive protein serine/threonine kinase—to the membrane in its
enzymatically active form. Sustained activation of PKC depends
on diacylglycerol generation from hydrolysis of additional lipids
such as phosphatidylcholine. The increase in the concentration of
intracellular free Ca2 and sustained PKC activation function
synergistically in promoting the expression of several nuclear
regulatory proteins and transcription of genes important for T-cell
growth and differentiation.
Calcineurin, a Ca2- and calmodulin-dependent serine/threo-
nine phosphatase (protein phosphatase 2B), participates in signal
transduction. Inhibition of the phosphatase activity of calcineurin
by CsA and FK506 is considered central to their immunosuppres-
sive activity [26—29].
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Table 1. Receptor counter-receptor pairs that mediate the physical and
informative interactions between T-cells and antigen-presenting cells
(APCs)a
T-cell
surface
APC
surface Functional response
Consequence of
blockade
LFAI ICAMI
Adhesion ImmunosuppressionICAMI LFAL
VLA4 VCAM1
CD8, TCR, CD3 MHCI
Antigen Recognition Immunosuppression
CD4, TCR, CD3 MHCII
CD2 LFA3
Costimulation ImmunosuppressionCD4OL CD4O
CD5 CD72
CD28 B7-1
Costimulation Anergy
CD28 B7-2
CTLA4 B7-1
Inhibition Immunostimulation
CTLA4 B7-2
a Inhibition of each protein-to-protein interaction, except that of
CTLA4 with the B7-l/B7-2 proteins, results in the inhibition of immune
response. CTLA4, present on activated but not resting T-cells, appears to
impart a negative signal.
Co-stimulatoty signals. Stimulation of T-cells via the TCR/CD3
complex alone, in the absence of co-stimulatory signals, induces
T-cell anergy/paralysis [30, 31]; full T-celI activation requires both
antigenic and co-stimulatoiy signals engendered by cell-to-cell
interactions among antigen-specific T-cells and APCs [30—32].
Table 1 lists the cell-surface proteins contributing to full T-cell
activation [32—37]. T-cell accessory molecules and their cognate
APC surface proteins represent target molecules for anti-rejection
therapy. Indeed, transplantation tolerance has been induced in
experimental models by targeting cell-surface molecules that
transmit co-stimulatory signals [38—40]. Antigen-presenting-cell-
derived cytokines (for example, IL-i and IL-6) also can provide
co-stimulatory signals that result in T-cell activation in vitro [41].
Prevention of cytokine production by APCs represents another
strategy for controlling the anti-allograft response.
In a fashion similar to T-cells, stimulation of B-cells also
depends on the antigenic signal and the co-stimulatory signal [42,
43]. The antigenic signal is generated by the interaction between
the specific antigen and the cell surface immunoglobulin. T-cell-
derived cytokines (for example, IL-2 and IL-4) and/or cell-to-cell
physical contact between T-cells and B-cells via specific receptor-
coreceptor pairs (for example, interactions between the CD4O
protein and its ligand CD4OL) function as co-stimulatory signal(s)
[43].
Immune eJfector mechanisms. Allograft rejection is contingent
upon the coordinated activation of alloreactive T-cells and APCs.
Through the release of cytokines and cell-to-cell interactions, a
diverse assembly of lymphocytes—including CD4 + T-cells,
CD8 + cytotoxic T-cells, antibody-forming B-cells, and other
inflammatory leukocytes—is recruited into the anti-allograft re-
sponse (Fig. 1).
The net consequence of cytokine production and acquisition of
cell-surface receptors for these transcellular molecules is the
emergence of antigen-specific and graft-destructive T-cells (Fig.
1). Cytokines also facilitate the humoral arm of immunity by
promoting the production of antibodies that can damage the
transplanted organ via complement-dependent and/or antibody-
dependent cell-mediated cytotoxicity mechanisms. Moreover,
IFN-y and TNFa can amplify the ongoing immune response by
upregulating the expression of HLA molecules as well as co-
stimulatory molecules on graft parenchymal cells and APCs.
Donor antigen-specific cytotoxic T-lymphocytes (CTL) and anti-
HLA antibodies have been identified during or preceding a
clinical rejection episode [44, 45].
Molecular investigation
A highly sensitive method, reverse transcriptase-polymerase
chain reaction (RT-PCR) permits detection of mRNA of interest
[46, 471. This powerful technology is being utilized to explore the
molecular mechanisms of rejection [48—531. In our studies, we
investigated intragraft expression of mRNA encoding granzyme
B, perform IL-2, IL-4, IL-b, and IFN-y.
Donor-specific CTL are present in human renal allografts and
experimental organ grafts during rejection [44, 54]. Given the
importance of CTL to the rejection process, we have determined
intragraft expression of mRNA encoding granzyme B, a pheno-
typic and functional marker for killer cells [55—59]. The demon-
stration by Strom's laboratory that intragraft expression of gran-
zyme B is a strong correlate of acute renal allograft rejection [48,
49] and the observation that granzyme B participates in inducing
rapid DNA fragmentation [60], provided the additional rationale
for us to investigate the relationship between intragraft expression
of granzyme B and acute rejection.
Performs are pore-forming molecules structurally related to the
ninth component of complement [61] that perforate target cell
membranes [62]. A role for perform in CTL killing is supported by
studies in which the exogenous administration of perform anti-
sense oligonucleotides in vitro significantly diminishes CTL-me-
diated target cell lysis [63]. Additional in-vitro assays have dem-
onstrated a close temporal relationship between the expression of
both granzyme and perform proteins and the development of
functional cytolytic capability [64]. Mice bearing two copies of a
disrupted perform gene (perform gene knockout mice) manifest a
gross deficiency in CTL and NK cell activity [65]. Granzyme B and
perform thus represent molecular mediators of the lytic program
of the cytotoxic cells [66, 67].
A large body of data, clinical and experimental, supports a
cardinal role for the IL-2 system in the generation and expression
of anti-allograft immunity [68—71]. The rationale for studying
intragraft IL-2 mRNA expression is strengthened further by the
correlation between IL-2 mRNA expression and graft rejection
[50, 52, 72], Interferon gamma, a secretory product of activated
T-cells, promotes the expression of HLA antigens that serve as the
major stimulus for the initiation of, and subsequently as the target
for, the anti-allograft response [73, 74]. That IFNy can enhance
not only graft immunogenicity but also the cytotoxic armamentar-
ium of the graft recipient represents the rationale for our inves-
tigation of IFNY mRNA expression. Nast et al [53] have detected
IFNy mRNA in fine-needle aspiration biopsy specimens obtained
from renal allograft recipients undergoing acute rejection [53].
Interleuken-4, a T-, mast-, and B-cell product [75] and an
autocrine growth factor for a subset of CD4+ T-cells, the TH2
I
I
I
I
II
+
CD4
ILl
Cytokines
I L-2
IFN-y
etc
AZA
- 7
I
Rapamycin
RS-61 443
a
Renal allograft
1292 Nephrology Fonim: Renal allograft rejection
Fig. 1. The anti-allograft repertory and its
regulation. HLA, the primary stimulus for the
initiation of the anti-allograft response; cell-
surface proteins participating in antigenic
recognition and signal transduction;
contribution of the cytokines and multiple cell
types to the immune response; and the
potential sites for the regulation of the anti-
allograft response are illustrated. Site 1:
minimizing histoincompatibility between the
recipient and the donor by HLA matching; site
2: prevention of cytokine production by APCs
with corticosteroids; site 3: blockade of antigen
recognition (e.g., OKT3 mAbs); site 4:
inhibition of T-cell cytokine production (CsA,
FK.506, and steroids); site 5: inhibition of
cytokine activity (e.g., anti-IL-2 antibody,
rapamycin); site 6: inhibition of cell cycle
progression (e.g., anti-IL-2 receptor antibody);
site 7: inhibition of clonal expression (e.g.,
azathioprine, RS-61443, rapamycin); site 8:
prevention of allograft damage by masking
target antigen molecules (e.g., antibodies
directed at adhesion molecules). (HLA-class I:
HLA-A, -B, and -c antigens; HLA-class II:
HLA-DR and -DQ antigens; APC: antigen-
presenting cell; CsA: cyclosporine A; AZA:
azathioprine; IL-2, interleukin-2; IFN-y:
interferon y; NK cells: natural killer cells; RS-
61443: mycophenolate mofetil; FK506:
tacrolimus; rapamycin: sirolimus. (Reproduced
with permission from STROM TB,
SUTHANTHRAN M: Mechanisms of graft
rejection, in ASTP Lectures in Transplantation,
edited by SAYEGH MH, TURKA LA,
Philadelphia, CoMed Communications, Inc.,
1996.)
CD4+ T-cells, is not detectable in acutely rejecting experimental
islet allografts [72]. On the other hand, intragraft IL-4 transcripts
are present in anti-CD4 mAb-treated recipients of rat cardiac
allograft during tolerance induction [761. Also, IL-4 mRNA
expression is not inhibited in the anergized cells [311. Thus, IL-4
might mitigate the anti-allograft response and facilitate graft
function. In this formulation, IL-4 mRNA expression is hypothe-
sized to be a negative correlate of allograft rejection.
Interleuken-lO, formerly called cytokine synthesis inhibitory
factor, is produced by TH2 CD4 + T-cells, monocytes, and other
cell types [77, 78]. New data also implicate THI cells as a source
of IL-b [79]. Interleuken-lO inhibits APC function by blocking
expression of class-lI MHC. It also inhibits synthesis of multiple
cytokines including IFNy and IL-2. Hence, IL-b blocks antigen
driven proliferation of TH1 cells [78], the major source of IL-2
and IFNY. Overexpression of IL-b theoretically could block
rejection. On the other hand, IL-b is a candidate cytokine for
promoting allograft rejection, because this multifunctional
polypeptide can stimulate immune responses, including the gen-
eration of CTL and production of antibodies by B-cells [80, 81].
Mosman and Coffman originally determined that the murine
CD4 helper T-cell can be divided into two distinct and mutually
exclusive subsets: TH1 cells that produce IL-2, IFNy, and lym-
photoxin; and TH2 cells that secrete IL-4, IL-5, IL-6, and IL-b
[82]. This differential pattern of cytokine production, also re-
ported with human T-cell clones, has significant implications for
immunity to infections, for example, human leprosy [83—88]. An
attractive hypothesis is that the activation of TH1 cells results in
rejection and that the activation of TH2 cells facilitates graft
accommodation [89, 90].
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Design Development and Authentication of Granzyme B Competitor DNA Construct
ci)(I)
+0_ O
0) 0)C
c',l C\j
- Q_
C 0(0 (0 C!)
'— — cJ
The renal biopsy tissue from the patient under discussion was
assessed for intragraft gene expression. This assessment was
accomplished by isolation of total RNA from the renal biopsy
tissue, reverse transcription of mRNA into first-strand cDNA, and
amplification by PCR. This patient's renal biopsy specimen with
histologic features of acute rejection expressed mRNA encoding
granzyme B, perform, IL-2, IFNY or IL-b.
We and others have developed methods that permit precise
quantification of mRNA of interest [49, 91, 92]. Figure 2 displays
our design, development, and authentication of a competitive
DNA construct for the quantification of granzyme B mRNA by
competitive quantitative PCR. The primer design generates a 180
bp fragment length granzyme B PCR product containing MseI
restriction sites. The digestion of the granzyme B PCR product
with the restriction endonuclease MseJ yields subfragments of 82,
15, and 83 bp fragment lengths. The annealing and ligation of 82
and 83 bp fragments with the in-vitro synthesized 44 bp DNA
fragment bearing the appropriate cohesive ends yields a granzyme
B competitor fragment of 209 bp length. The agarose gel electro-
phoretic analysis, shown in panel B, demonstrates that these
fragments are indeed generated by this strategy.
We have utilized the 209 bp granzyme B construction DNA as
the competitor DNA for the quantification of granzyme B mRNA
prepared from renal allograft tissues including mRNA from the
biopsy sample obtained from the patient under discussion. Figure
3 illustrates the data from this patient. The clearly distinguishable
209 bp granzyme B construct and the granzyme B eDNA were
quantified by densitometric scanning, and the computation of data
yielded a value of 8.29 >< iO pmole of granzyme B mRNAJmg
of RNA.
We have investigated 127 renal allograft biopsy specimens for
qualitative intragraft gene expression [50, 511. Among the 127
biopsies, 82 were classified as acute rejection, based on Banif
criteria [13]. Granzyme B mRNA was detected in 59 of the 82
biopsies diagnosed as acute rejection and in only 17 of 45 biopsies
without histologic evidence of rejection. The correlation between
intragraft granzyme B mRNA expression and acute rejection was
significant at P < 0.0002 (Table 2). Among the cytokines studied,
intragraft expression of IL-b mRNA and of TL-2 mRNA signif-
icantly correlated with acute rejection (Table 2). In this study
comprising 127 renal allograft biopsy samples, intragraft expres-
sion of perform mRNA, IL-4 mRNA, or IFNY mRNA was not a
significant correlate of rejection.
Our intragraft mRNA expression studies [50, 51] have revealed
novel molecular correlates of rejection (Table 2) and suggest
several biologic features of potential clinical value. For example,
in view of the strong association between acute rejection and
intragraft expression of granzyme B mRNA demonstrated in our
study as well as in the pioneering studies of Strom's group [48, 49],
future anti-rejection strategies might include approaches to con-
strain the expression of this cytotoxic cell-specific protease re-
quired for rapid induction of DNA fragmentation and apoptosis.
On the other hand, since IL-2 mRNA was detected in only a few
biopsies with histologic features of rejection, and IFN-y mRNA
expression was not a correlate of rejection, current therapeutic
A
ci) ci)(I) Cl)
ci r..
82 h5
B
C') C')(0 (0
83
I Granzyme B PCR Product
(180 bp)
ci)
Cl)
+
Pr. 1
Pr.2Mse I
82bp l5bp 83bp
TTAA—TTAA
AATT AAT T
82bp 83bp
TTAA IAAT I
83
82 r
44 -
15 -44bpTAA
AAT
Ligation
I 52 V/,'Z4d//ti I_____________________________
Granzyme B Competitor
________________________________ (209 bp)
Fig. 2. Design, development, and authentication of granzyme B competitor construct for the quantification of granzyme B mRNA. The primer design, the
restriction sites for MseI, the subfragments (82, 15, and 83 bp) generated by MseI digestion, the insert DNA of 44 bp length, and the construct of 209
bp length are shown in A. Agarose gel electrophoretic validation of the granzyme B PCR product of 180 bp length following digestion with MseI, and
the creation of the construct of 209 bp length are shown in B. The insert DNA of 44 bp length, and the digestion with MseI of 209 bp length granzyme
B competitor construct yielding subfragments of 83, 82, and 44 bp lengths also are shown in panel B.
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Granzyme B: Quantification by Competitive PCR
Concentration of Competitor (pg)
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Fig. 3. Quantification of granzyme B mRNA by PCR. Serial dilutions of the 209 bp granzyme B construct were co-amplified with eDNA prepared from
the total RNA isolated from the renal allograft. Following 30 cycles of amplification, the PCR-amplified products were fractionated by 2% agarose gel
electrophoresis and the negatives of photographs of ethidium bromide-stained gels were scanned by laser densitometiy, computed, and plotted. The 123
bp repeat ladder (M) is also shown.
Table 2. Intragraft expression of mRNA encoding cytotoxins or
cytokines
Acute
rejection
Intragraft mRNA + — ph
Granzyme B
Granzyme B
IL-b
IL-lO
lL-2
IL-2
IL-4, IFN7,
or perform
a The Banif acute rejection criteria [131 were used to establish the
histopathologic diagnosis of 127 renal allograft biopsy specimens.bP value determined by Fisher's exact test.
C Numbers in brackets refer to numbers of renal biopsy specimens that
were positive or negative for a given mRNA.
strategies appear to be quite effective in preventing IL-2- and/or
IFNy-dependent immune mechanisms of rejection.
The cytokine synthesis inhibitory activity of IL-b and its ability
to constrain APC function of monocytes and the functional
programs of T-cells suggest that IL-I 0 might function in vivo as an
immunosuppressive cytokine. Our demonstration that intragraft
IL-lU mRNA expression is a positive correlate of acute rejection
(Table 2) [501, however, challenges this notion and favors instead
the hypothesis that this multifunctional cytokine might function in
vivo as an immunostimulatory polypeptide. Of the cytokines
evaluated, intragraft expression of IL-4 was the least common;
IL-4 mRNA was detected in only two of 87 renal allograft biopsies
studied for IL-4 expression. This lack of intragraft expression of
+ [76] 59 17
— [511 23 28 0.0002
+
—
+
—
[55]
[72]
[10]
[117]
46
36
10
72
9
36
0
45
0.0001
0.014
> 0.05
IL-4 mRNA is intriguing because IL-4 has been implicated in
tolerance in experimental models of transplantation [901, and
authentic tolerance in the clinical setting is quite uncommon.
Immunopharmacology of allografi rejection
CsA and FK5OO. Cyclosporine A, a small fungal cyclic peptide,
and FK506, a macrolide, block T-cell activation via similar
mechanisms [93]. The immunosuppressive effects of CsA and
FK506 depend on the formation of a heterodimeric complex that
consists of the drug (CsA or FK506) and its respective cytoplasmic
receptor protein, that is, cyclophilin and FK binding protein
(FKBP). Both these complexes bind calcineurin and inhibit its
phosphatase activity [26—29, 93], thereby inhibiting the de-novo
expression of nuclear regulatory proteins and T-cell activation
genes, that is, those encoding certain cytokines (for example,
IL-2), proto-oncogenes (for example, H-ras, c-myc), and receptors
for cytokines (for example, IL-2 receptor). Inhibition of IL-2
expression by CsA/FK506 is considered the primary mechanism
for their immunosuppressive activity (Figs. 1 and 4).
Corticosteroids. A short course of high doses of corticosteroids
often is used to treat acute rejection episodes. Corticosteroids
inhibit T-cell proliferation, T-cell-dependent immunity, and cyto-
kine gene transcription (including the IL-i, IL-2, IL-6, IFNy, and
TNFa genes) [94—96]. Although no individual cytokine can totally
reverse the inhibitory effects of corticosteroids on mitogen-stim-
ulated T-cell proliferation, a combination of cytokines is effective
in restoring T-celI proliferation [971. Inhibition by corticosteroids
of cytokine production represents an important rationale for its
use in the control of the anti-allograft response (Fig. 1).
Some of the cytokine genes possess a glucocorticosteroid
response element in the 5' regulatory region that serves as a target
•jçjc
Purine
Synthesis V
Raparnycin
Differentiation
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Fig. 4. Mechanism of action of
immunosuppressive drugs. CsA and FK506
(tacrolimus) inhibit transcription of T-cell
growth-promoting genes (e.g., IL-2); rapamycin
(sirolimus) blocks growth-factor-initiated signal
transduction; azathioprine, RS-61443
(mycophenolate mofetil), and mizoribine inhibit
purine biosynthesis. DSG (15-deoxyspergualin)
is an inhibitor of cell differentiation/maturation.
for the heterodimeric complex formed by the association of
corticosteroids with the intracellular glucocorticosteroid receptor
protein. Binding of this complex to the glucocorticosteroid re-
sponse element represents a potential mechanism for blocking
gene expression. This mechanism, however, does not fully account
for the inhibitory effects of corticosteroids on the expression of
several cytokine genes. Blockade of IL-2 gene transcription, for
example, involves impairment of the cooperative effect of several
DNA binding proteins [98—1001, although the IL-2 gene does not
possess a glucocorticosteroid response element.
An additional mechanism for the ability of glucocorticoids to
inhibit the transcription of genes that do not contain a glucocor-
ticoid response element also has been identified. Glucocorticoids
induce the transcription of IKBa gene; the resultant IKBa protein
then binds NF-KB transcription factor and prevents its transloca-
tion into the nucleus [101, 102]. Thus, genes that are regulated by
the DNA-binding protein NF-KB acquire sensitivity to glucocor-
ticoids despite the absence of a cis-acting glucocorticoid response
element.
Azathioprine. Azathioprine is the 1-methyl-4-nitro-5-imidazolyl
derivative of 6-mercaptopurine [103]. A purine analogue, azathio-
prine functions as a purine antagonist and thereby inhibits cellular
proliferation (Figs. I and 4). Allopurinol blocks the catabolism of
azathioprine and can dramatically increase bone marrow suppres-
sion. Azathioprine often is used in conjunction with CsA or
tacrolimus and corticosteroids in maintenance drug protocols.
Although the application of azathioprine diminishes the incidence
and intensity of rejection episodes, it is of no value in the therapy
of ongoing rejection.
Mycophenolate mofetil. Mycophenolate mofetil (RS-61443), the
semisynthetic derivative of the fungal antibiotic, is converted into
its active metabolite mycophenolic acid, which inhibits allograft
rejection in rodents, diminishes proliferation of T- and B-lympho-
cytes, decreases generation of cytotoxic T-cells, and suppresses
antibody formation [104, 105]. Mycophenolic acid is an effective
and reversible inhibitor of inosine monophosphate dehydroge-
nase. T-cells as well as B-cells depend on both the de-novo and
salvage pathways for purine nucleotide synthesis, whereas other
cells satisfy their demand for purines via the salvage pathway.
Thus, mycophenolic acid is a relatively selective inhibitor of T-
and B-cell proliferation via its ability to prevent guanosine and
deoxyguanosine biosynthesis (Figs. 1 and 4).
The efficacy and safety of mycophenolate mofetil for the
prevention of acute rejection during the first six months after
renal transplantation have been evaluated in a randomized,
double-blind multicenter study in Europe and the U.S. [106, 107].
In the European study, mycophenolate mofetil was added to a
regimen of CsA and steroids. In the U.S. investigation, mycophe-
nolate mofetil was added to a regimen of CsA, steroid, and
antithymocyte globulin (ATGAM) induction therapy. The patient
and graft survival rates, at six months post transplantation, were
quite similar with mycophenolate mofetil- or azathioprine-supple-
mented regimens. The use of mycophenolate mofetil (2 g or 3
glday) significantly reduced the incidence and severity of biopsy-
proven acute renal allograft rejection. This decrease in acute
rejection episodes with mycophenolate mofetil might benefit the
long-term outcome of renal allografts, as acute rejection is a risk
factor for chronic rejection, as I discussed earlier.
Mizoribine. Like azathioprine and mycophenolic acid, this imi-
dazole nucleoside blocks the purine biosynthetic pathway and
inhibits mitogen-stimulated T- and B-cell proliferation [108, 109]
(Fig. 4). The antiproliferative effect is linked to a decrease in
guanine ribonucleotide pools. Mizoribine prolongs graft survival
in several preclinical models, and it is undergoing clinical testing
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as a substitute for azathioprine in renal transplant recipients in
Europe after having been approved in Japan. Mizoribine appears
safe and, unlike azathioprine, it might not be myelo- or hepato-
toxic.
Rapamycin. Rapamycin (sirolimus), a macrocyclic antibiotic
produced by Streptomyces hygroscopicus in a fashion similar to
tacrolimus, binds to FKBP [110, 1111. Yet sirolimus and tacroli-
mus affect different and distinct sites in the signal transduction
pathway (Figs. I and 4). Whereas sirolimus blocks IL-2 and other
growth-factor-mediated signal transduction [1 10—I 12], tacrolimus
(or C5A) has no such ability. Also, the sirolimus-FKBP complex,
unlike the tacrolimus-FKBP complex, does not bind calcineurin.
The cellular receptor(s) for the sirolimus-FKBP complex are
being elucidated. Two proteins, designated as targets of rapamy-
cm (TORi and TOR2), with a relative molecular mass of 282 kD
each and with 68% homology, originally were identified as
receptors [113]. A protein complex comprised of 245 kD and 35
kD components, with about 40% sequence similarities to yeast
TORi and TOR2 and homologous to the catalytic domain of p110
subunit of P1-3 kinase, recently have been identified as putative
targets for the drug-immunophilin complex in mammalian cells
[114].
The antiproliferative activity of sirolimus appears to be a
consequence in part of the sirolimus-FKBP complex blocking the
activation of the 70 kD S6 protein kinases involved in cell
proliferation. Additional cell cycle regulatory proteins, cyclin-
dependent kinase-2 (CDK2) and CDK4, are also inhibited by
sirolimus. Sirolimus blocks the Ca2-independent CD28/B7 co-
stimulatory pathway. The CD28 pathway participates in the
downregulation of IKBa, a cytosolic protein that prevents nuclear
translocation of DNA-binding protein NF-KB, and sirolimus
prevents the CD28 co-stimulatory signal responsible for I,Ba
downregulation [115].
Sirolimus can constrain the proliferation not only of traditional
immune cells (for example, T-cells), but also that of additional cell
types such as smooth muscle cells [116]. Thus, sirolimus might be
effective in the prevention and/or progression of graft vascular
disease (for example, chronic rejection).
Sirolimus is being evaluated in phase-I and phase-Il clinical
trials of organ transplantation [111, 117]. In a preliminary study,
supplementation of a cyclosporine-based immunosuppressive reg-
imen with sirolimus was associated with a reduction in the
incidence of acute renal allograft rejection. Nephrotoxicity and
hypertension thus far have not been a serious consideration.
Thrombocytopenia and hyperlipidemia appear to respond to a
reduction in drug dosage.
15-Deoxyspergualin (DSG). Deoxyspergualin is a synthetic ana-
logue of spergualin that exerts powerful immunosuppressive
properties in preclinical transplant models. Although the mecha-
nism by which DSG inhibits the immune response is unknown, a
member of the heat shock protein 70 family has been identified as
an intracellular DSG binding protein [118, 119]. Deoxyspergualin
is unique in that it prevents the differentiation of T- and B-cells
into mature effector cells (Fig. 4). The efficacy of DSG is being
tested in the U.S. in phase-Ill trials, in renal transplant recipients
undergoing rejection, and in highly sensitized recipients. Deoxy-
spergualin might be effective as a rescue therapy in renal graft
recipients who have not responded to high-dose corticosteroid
therapy.
Anti-T-cell and other antibodies directed at cell-sutface proteins.
Many centers use polyclonal anti-lymphocyte antibodies (for
example, ALG, ATG) or monoclonal antibodies (for example,
OKT3) as induction therapy for 7 to 14 days in the immediate
post-transplant period [120—122]. This strategy establishes an
immunosuppressive umbrella that enables early engraftment with-
out CsA usage during the early post-transplant period. Antibody
induction protocols have reduced the incidence of early rejection
and are particularly beneficial for patients at high risk for immu-
nologic graft failure, for example, broadly presensitized patients
or patients undergoing a second transplant [1, 5].
Polyclonal antibodies such as ATG and ALG also are used as
anti-rejection agents, especially in patients with steroid-resistant
acute rejection episodes [120—122]. The clinical efficacy of poly-
clonal anti-lymphocyte antibodies is similar to that of monoclonal
antibodies, such as OKT3, in reversing rejection. The major
advantage of polyclonal reagents over monoclonal antibodies is
that the former interact with multiple cell-surface proteins impli-
cated in T-cell signaling. The significant disadvantages of poly-
clonal antibodies include the requirement of administration of
large amounts of heterologous foreign proteins (the antibodies
are usually raised by immunizing horses or rabbits) and the
potential for serum sickness. Infectious complications also are
observed with the clinical use of polyclonal anti-lymphocyte
antibodies. Viral infection, such as primary cytomegalovirus, or
reactivation is not an uncommon complication of therapy with
polyclonal anti-lymphocyte antibodies. Nevertheless, polyclonal
anti-lymphocyte antibodies represent useful immunosuppressive
drugs, especially for high-risk organ graft recipients.
The OKT3 monoclonal antibody is the prototypic monoclonal
antibody used in clinical organ transplantation. This monoclonal
antibody binds to the e-chain of the T-cell CD3 proteins and
modulates the T-cell antigen receptor/CD3 complex from the cell
surface. In a randomized, multicenter trial in the U.S., 94% of
acute rejections in recipients of primary cadaveric renal trans-
plants were reversed with OKT3, compared to 75% with conven-
tional high-dose corticosteroids [123].
The first few doses of OKT3 are associated with fever, chills,
and a capillary leak syndrome, hypotension, pulmonary edema,
nephropathy, and encephalopathy. A few cases of irreversible
graft failure due to graft thrombosis also have been observed with
OKT3. Cytokines, especially TNFa, have been implicated as a
basis for some of these effects. Rigorous attention to the fluid
status of the graft recipient and premedication with high-dose
steroids have reduced the side effects of OKT3. Cyclosporine,
pentoxifylline, indomethacin, and anti-TNFa monoclonal anti-
bodies also appear useful in reducing the side effects of OKT3
[124—127].
Monoclonal antibodies that react with the invariant region of
the a or the /3 chains of T-cell antigen receptor also are quite
effective in reversing rejection [128, 129]. Anti-IL-2 receptor a
(CD25) monoclonal antibodies also can reduce the incidence of
early rejection episodes [70, 71]. Monoclonal antibodies specific
for cell-surface proteins implicated in the generation of co-
stimulatory signal(s) also are being explored for their efficacy in
the clinic. Anti-LFA-l (CD1IA), anti-ICAM-l (CD54), OKT4A
(anti-CD4), and campath-IH (CD52) are being tested in solid
organ recipients [130, 131]. Additional co-stimulatory molecules
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expressed on the T-cells and/or APCs also are attractive candi-
dates for the fine regulation of alloimmunity. Monoclonal anti-
bodies directed at the CD2 antigen [40, 1321 and soluble fusion
proteins capable of blocking the CD28-B7 co-stimulatory pathway
appear promising based on their efficacy in preclinical models of
transplantation [39, 133]. Monoclonal antibody usage has been
hampered by the recipient's immune response to the monoclonal
antibodies. The "humanization" of murine mAbs [134], wherein
the antigen-binding sites are genetically engineered onto a human
immunoglobulin background, might minimize the problem.
Concluding remarks
The basic immunosuppressive protocol used in most transplant
centers involves multiple drugs, each directed at a discrete site in
the T-cell activation cascade and each with distinct side effects
(Fig. 1). Cyclosporine, azathioprine, corticosteroids, tacrolimus,
and mycophenolate mofetil already are approved by the FDA,
while the clinical efficacy of sirolimus, mizoribine, and DSG is
being explored in clinical trials. The immunosuppressants can be
classified, on the basis of their primary site of action, as inhibitors
of transcription (CsA, tacrolimus), inhibitors of nucleotide syn-
thesis (azathioprine, mycophenolate mofetil, and mizoribine);
inhibitors of growth-factor signal transduction (sirolimus); and
inhibitors of differentiation (DSG) (Fig. 4). Polyclonal antibodies
and monoclonal antibodies directed at cell-surface proteins are
used as induction therapy and/or anti-rejection drugs. Clearly, the
transplant clinician now has a greater choice in the selection and
application of immunosuppressants in the clinic for the preven-
tion of allograft rejection. Mechanistic insights, gained by addi-
tional immunologic and molecular investigations, should pave the
way not only for further refinement of the therapeutic arsenal of
the transplant clinician, but also for the development and imple-
mentation in the clinic of protocols capable of engendering
transplantation tolerance [135, 136].
Questions and answers
DR. JOHN T. HARRINGTON (Dean, Tufts University School of
Medicine Boston, Massachusetts): Tell us more about signaling
and co-stimulatory signaling. Specifically, I'm interested in the
quantitative aspects of it rather than simply the directional
aspects. In the early phases of signaling, which of the second
messengers or signals are quantitatively more important? Second,
can we attack at those levels?
DR. SUTHANTHIRAN: Full T-cell activation depends on the
antigenic signal and the co-stimulatory signals. The antigenic
signal is generated by the physical interactions between the TCR
a,3-heterodimer and the antigenic peptide displayed by MHC on
the APCs. The obligatory co-stimulatory signal is generated by the
interactions between additional T-cell surface molecules and their
specific counter-receptors expressed on the APCs (Table 1).
You raise an important issue regarding the quantitative aspects
of the signaling process. Although each of us has a favorite
co-stimulatory molecule, existing data do not permit a hierarchical
ranking for the relative strengths of co-stimulatory signals gener-
ated via different T-cell molecules. Also, CTLA4, a homologue of
CD28 antigen, generates a negative rather than a stimulatory
signal [37, 137]. Nonetheless, blockade of co-stimulatory signals
can result in antigen-specific T-cell non-responsiveness, and this
outcome, termed T-cell anergy [31], is being explored in several
laboratories in the hope of creating an allograft-permissive toler-
ance. in preclinical models of transplantation, blockade of the
CD28/B-7 pathway [39, 138], and targeting of additional cell-
surface proteins ICAM-1 and LFA-1 [38], CD4O ligand [139], and
the CD2 antigen [40] have induced transplantation tolerance
and/or prolonged graft survival. As we move up the Darwinian
scale, targeting a single co-stimulatory molecule might not be
sufficient, and multiple cell-surface molecules might need to be
simultaneously targeted for the induction of transplantation to!-
erance in humans.
DR. ANDREW J. KING (Division of Nephrology, New England
Medical Center, Boston, Massachusetts): Our approach to immu-
nosuppression at this time is very blunt: we use agents that have
nonspecific immunosuppressive properties and thereby submit the
patient to an increased risk of infection and malignancy. The
major goal in transplantation is the induction of specific tolerance.
Could you speculate on ways that specific tolerance could be
induced?
DR. SUTHANTHIRAN: Deletion of autoreactive T-cells and B-
cells, and additional immune mechanisms including suppressor,
veto, and anergy, have been advanced as the basis for tolerance to
self-antigen and the avoidance of auto-immunity [140—142]. The
central question is whether the principles of self-tolerance can be
exploited for the induction of transplantation tolerance. I believe
that several potential pathways exist. In addition to blockade of
co-stimulatory signals [138], several innovative strategies are
worthy of exploration in the clinical setting: induction of a mixed
chimeric state wherein the donor bone-marrow-derived cells
induce transplantation tolerance [143], intrathymic inoculation of
donor antigens [144], and exploitation of the Fas/Fas ligand
system [145] implicated in the immune-privileged nature of
certain sites (for example, anterior chamber of the eye [146]) and
tissues (for example, testis [147]).
DR. ANDREW S. LEVEY (Division of Nephrology, New England
Medical Center): My question relates to the hope for developing
methods for immunologic monitoring of the graft. Currently, we
recognize episodes of acute rejection by monitoring renal func-
tion. The scheme you presented today of the process of chronic
rejection might not cause overt renal dysfunction until it is far
advanced. Our ability to recognize the early phase of chronic
rejection thus would clearly depend on some other marker of
renal injury or immune activation. Are we any closer to develop-
ing methods for immunologic monitoring?
DR. SUTHANTHIRAN: Our current method of diagnosing rejec-
tion is somewhat like the "morning-after pill" approach. As you
point out, we make the diagnosis after the fact, and we miss the
upstream immunologic events. I believe that by using molecular
techniques such as the RT-PCR, we can identify the immunologic
phase that precedes the histologic/structural manifestations. In a
murine islet cell transplantation model, we [40] and Strom's group
[72] have detected intragraft expression of pro-inflammatory
genes prior to graft dysfunction manifested by hyperglycemia.
Fine-needle aspiration biopsies of the renal allografts, for exam-
ple, can be performed twice weekly during the first month of
transplantation and less frequently (at about 6-month intervals) in
the latter phase, and RT-PCR could be used to detect gene
expression in the fine-needle aspirates. Indeed, Daliman and
colleagues [52] and Nast and coworkers [53] already have initiated
such studies and have shown that intrarenal expression of mRNA
encoding IL-2 [521 or IFNY [53] precedes acute rejection of renal
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allografts. Our data suggest that intrarenal expression of gran-
zyme B mRNA and of IL-lU mRNA would be helpful in antici-
pating acute rejection, and that expression of TGF-p1 is a
harbinger of chronic rejection. The list of mediators certainly will
increase in the future, given the complexity of the rejection
process. The clinical usefulness of these molecular correlates
needs to be assessed in prospective clinical trials.
DR. HARRJNGTON: If you did PCR tests on a renal biopsy, how
soon would the information come back?
DR. SUTHANTHIRAN: The turn-around time can be less than 24
hours. In the near future, with refinements in the RNA isolation
procedure and automation of the several steps of RT-PCR, the
time could be as little as 10 to 12 hours.
DR. Nicoios E. MADIAS (Chief Division of Nephroloy, New
England Medical Center): Could you address the issue of immu-
nogenicity of OKT3 and other monoclonal antibodies and its
clinical implications?
DR. SUTHANTHIRAN: Induction therapy with OKT3 mAb is
associated with approximately a 50% incidence of a human
anti-mouse antibody (HAMA) response [121, 148]. The antibod-
ies might be directed at the isotype or at the idiotype. The
anti-idiotypic antibodies are thought to interfere with OKT3
efficacy, especially when present in high titers. An OKT3 dosage
higher than the usual 5 mg dose might be effective in the presence
of such immunization. Mycophenolate mofetil (MMF) reduces
human IgG anti-ATGAM antibody formation in renal allograft
recipients [149]. Thus, concomitant therapy with MMF also might
reduce the HAMA response.
Immunization against other monoclonal antibodies used in
clinical transplantation has not been studied in detail. The immu-
nogenicity of anti-CD4 mAbs or anti-CD25 mAbs can be expected
to be less, because these mAbs, unlike OKT3, are not potent
stimulators of T-cells.
DR. MADJAS: Does the "humanization" of murine monoclonal
antibodies adversely affect other properties of these molecules,
such as the binding affinity for antigens?
DR. SUTI-1ANTHIRAN: Humanized anti-CD4 mAb and anti-CD25
mAb are being investigated in clinical trials. The half-life is
reported to be longer, and the binding affinity appears to be
unaltered.
DR. MADIAS: Regarding your results on the intragraft expres-
sion of cytokines, could it be that the increased expression of
IL-b mRNA in acute rejection reflects merely a secondary
"compensatory" response to immunostimulatory cytokines rather
than mechanistic contributions to acute rejection?
DR. SUTHANTHIRAN: The issue of whether IL-lU functions
exclusively as an anti-inflammatory cytokine or whether it can also
act as a pro-inflammatory polypeptide remains unresolved. Some
of the biologic activities of IL-b, such as inhibition of TH1
cytokine production and macrophage deactivation [78], favor a
graft-protective role for IL-lU. On the other hand, the ability of
IL-lU to induce differentiation of precursors of cytotoxic T-cells
[80] and to stimulate B-cells [81] suggests a graft-destructive role.
Our clinical data showing that intrarenal IL-lU mRNA expression
is a correlate of acute rejection [50], and our finding in a murine
islet cell transplantation model that IL-b mRNA is expressed in
the rejecting allografts and not in the tolerated grafts [40], suggest
a pro-inflammatory role for IL-b. Our consideration of IL-b as
a contributor to acute rejection is supported by the following
observations: (1) transgenic expression of IL-b in murine pan-
creatic f3 cells [1501 or a cells [151] accelerates the onset of
diabetes in NOD (nonobese diabetic) mice; (2) IL-b transgene
does not prevent rejection of islet allografts [152]; and (3)
administration of an IL-b fusion protein accelerates, rather than
retards, islet graft rejection in a murine islet cell transplantation
model [153].
DR. JULIA R. NEURINGER (Divison of Nephrology, New England
Medical Center): I have another question in relation to the
RT-PCR technique. When evaluating living-unrelated donors or
choosing from a pool of similarly matched living-related donors,
could one use RT-PCR to further distinguish who is the most
compatible? In other words, would measuring granzyme B in vitro
give you additional data that would help in making this decision,
or would it provide much more information than a standard MLC
test?
DR. SUTHANTHIRAN: It is an interesting suggestion. One could
even perform the test in the presence of an immunosuppressant
such as cyclosporine and identify not only donor-specific immune
responsiveness but also susceptibility of that response to immu-
nosuppressants.
DR. BERTRAND JABER (Nephrology Fellow, New England Medical
('enter): Since cyclosporine acts as a pro-drug, has anyone re-
ported a natural mutant of cyclophilin that promotes a natural
resistance to cyclosporine? If so, this observation might explain
graft salvage with FK506 when cyclosporine fails; perhaps this
effect is conveyed through the FK506 binding protein-FK506
interaction, a different immunophilin-ligand complex.
DR. SUTFIANTHIRAN: I am not aware of a naturally occurring
cyclophilin mutant in humans that either fails to bind CsA or after
binding CsA fails to target and inactivate calcineurin. However,
mutations in cyclophilin that alter its affinity for CsA and for
calcineurin binding and inhibition have been found in the CsA-
sensitive fungus Saccharomyces cerevisiae [154]. Differential ex-
pression and/or activity of cyclophilin and FK506 binding protein
is a fascinating hypothesis for FK506 graft salvage in patients
failing CsA therapy.
DR. AJAY SINGH (Division of Nephrology, New England Medical
Center): One of the benefits of FKSO6, suggested in a recent study,
is its use as rescue therapy in patients with recurrent or resistant
rejection who are taking cyclosporine [1551. Could you comment
on this study and your own practice in these difficult cases?
DR. SUTHANTHIRAN: The first clinical application of FK506 was
in the treatment of cyclosporine-resistant liver allograft rejection
[156]. Since then, FK506 has been used in the treatment of
rejection of renal allografts and pancreatic allografts [157]. The
renal allograft data, recently updated [158], suggest a long-term
benefit as well. In my opinion, FK506 rescue therapy is a valuable
addition to the anti-rejection arsenal, and I would consider using
it in patients with two or more rejection episodes despite receiving
cyclosporine therapy.
DR. JABER: Using a rat aortic allograft model for the study of
chronic rejection, Steele et al demonstrated that treatment with
mycophenolate mofetil significantly inhibited intimal proliferation
at three months, when compared to untreated animals and
animals receiving cyclosporine at a dose of 2.5 mg/kg/day [159].
From these observations, can you speculate on a potential inhib-
itory effect of mycophenolate mofetil on TGF-j3 for the preven-
tion of chronic graft vasculopathy/rejection?
DR. SUTHANTHIRAN: Mycophenolate mofetil (MMF) prevents
chronic rejection in a rat renal allograft model [160]. In this
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model, TGF-f31 is hyperexpressed during chronic rejection [161].
However, a direct inhibitory effect of MMF on TGF-/31 expression
has not been demonstrated. Besides its antiproliferative effect on
immune cells, mycophenolate mofetil inhibits smooth muscle cell
proliferation as well as reduces N-linked glycosylation of adhesion
molecules [104, 105]. These additional properties might be mech-
anistically relevant for the prevention of chronic rejection. Also,
the clinical trials of MMF have demonstrated a reduction in the
incidence of acute renal allograft rejection [106, 107], a risk factor
for chronic rejection [6].
DR. MADIAS: Could you please update us on the mediation of
fibrogenesis by cyclosporine A?
DR. SUTHANTHIRAN: We reported in 1991 that cyclosporine
induces TGF-/31 hyperexpression in stimulated normal human
T-cells [91]. We also have noted similar stimulatory activity with
non-immune cells [162]. Because TGF-f31 is a potent fibrogenic
cytokine [163, 164], we proposed the hypothesis that CsA's
stimulatory activity on TGF-p1 is a mechanism for the fibrosis
associated with CsA nephrotoxicity [91, 162]. Our supposition has
received support from the recent findings that CsA-treated mice
or rats hyperexpress TGF-f31 [165, 166] and that CsA nephrotox-
icity is associated with heightened intrarenal expression of
TGF-131 [167]. In this model, additional downstream events
conducive to fibrosis, such as increased expression of plasminogen
activator inhibitor-i and of fibronectin, also have been noted
[167].
DR. MADIAS: Could you comment on the impact of the new
knowledge presented today on making anti-rejection therapy
safer? Also, under what circumstances do you recommend cessa-
tion of anti-rejection therapy?
DR. SUTHANTHIRAN: By investigating the molecular status of the
graft, we hope to refine anti-rejection therapy in three important
ways. First, the molecular studies might predict the onset of
rejection. This information should help in early intervention with
anti-rejection therapy. Second, molecular mechanisms of a given
rejection episode can be defined. In the future, in addition to
designating a rejection episode as acute or chronic, cellular or
humoral, we also might characterize an episode of rejection as
granzyme B rejection or IL-2 rejection. If we can accomplish this
level of precision, we might be able to provide more specific
therapy than that currently available. The third goal is to develop
reliable prognostic indices regarding reversibility of a given rejec-
tion episode. This should provide better guidelines for cessation
of anti-rejection therapy. At present, the decision to stop therapy
is primarily based on irreversible renal biopsy changes, markedly
impaired blood flow as assessed by renal scan, and the presence of
other co-morbid conditions such as infection.
DR. HARRINGTON: I have two questions. You mentioned that
using cytokine profiling, you can divide T-cells into TH1 and TH2
cells. What can we do to affect the relative distribution of these
cells? What would such alterations do to the likelihood of
transplant rejection or transplant graft function?
DR. SUTI-1ANTHIRAN: The THI/TH2 paradigm for transplanta-
tion is that TH1 cytokines IL-2 and IFN-y are graft destructive
and the TH2 cytokine IL-4 is tolerogenic [89, 90]. In preclinical
models, tolerance induction is indeed associated with repression
of THI cytokines and expression of TH2 cytokines [168]. The
universality of the principle is, however, tempered by the obser-
vation that IL-2-deficient mice reject islet allografts [169]. Then
there is also the observation that IL-b, originally considered a
TH2 product [170], is also produced by TH1 cells [79]. In clinical
transplantation, the jury is still out regarding the consequences of
TH1 activation versus TH2 activation.
DR. HARRINGTON: My second question is, has anyone per-
formed studies in patients with acute crescentic glomerulonephri-
tis comparable to the studies you've done in patients with
transplant graft rejection? What kinds of molecular signals or
intragraft gene expression can you find in those illnesses as
compared with what is found in transplant rejection?
DR. SUTHANTHIRAN: Interleukin-2 receptor a (CD25) mRNA
[171], TNF-a mRNA [172], and extracellular matrix receptors
[173] have been detected in human crescentic glomerulonephritis.
Increased TGF-f31 mRNA expression also has been reported in
human diabetic nephropathy [174], and in biopsy specimens
characterized by increased extracellular matrix accumulation [175,
176]. Upregulation of tissue factor has been observed in a rabbit
model of crescentic glomerulonephritis [177], and elegant data
suggest a causative role for IL-i in the progression of crescentic
glomerulonephritis in the rat model [178, 179].
DR. B.V.R. MURTHY (Clinical Research Fellow, Division of
Nephrology, New England Medical Center): The approach to
immunosuppression has mostly been directed towards T-cell
antigen recognition and response. Are there any pharmacologic
means of blocking the NK cells which, as we know, can also
mediate rejection of the allograft?
DR. SUTHANTHIRAN: Drugs such as cyclosporine and corticoste-
roids can be expected to affect the activation of NK cells, as these
agents block production of IL-2 and interferon gamma, and those
cytokines stimulate NK cell activity. However, we do not currently
use an NK-cell-specific drug in clinical transplantation.
DR. SINGH: You alluded to the hypothesis that the activation of
TH1 cells results in rejection, whereas the activation of TH2 cells
leads to graft accommodation. Could you update us on studies
directed at validating this hypothesis? Also, does treatment of
rejection change the TH1/TH2 balance?
DR. SUTHANTFIIRAN: As I mentioned earlier, TH1 activation
resulting in rejection, and TH2 activation engendering tolerance,
are observed in some but not all experimental models. Recent
work showed that IL-4 knockout mice neither reject allografts in
an accelerated fashion, nor are they resistant to CTLA4Ig therapy
[180]. Thus, at least in murine transplantation models, IL-2 and
IL-4 are not absolute requirements for rejection [169, 180] and the
absence of IL-4 does not preclude prolonged survival of allografts
in mice treated with CTLA4Ig [180]. Also, INF-y knockout mice
reject cardiac allografts as vigorously as do wild type, and the
rejected allografts display mRNA encoding IL-2, IL-4, and IL-b
[181]. Thus, the TH1/TH2 hypothesis is not fully supported by
existing data. I am not aware of clinical studies determining the
effect of anti-rejection therapy on THI1TH2 balance.
DR. SINGI-I: Several groups have presented data on blocking the
CD28 ligands B7—1 and B7—2 using CTLA4Ig both in experimen-
tal renal and cardiac transplantation [reviewed in Ref. 138]. One
of the potentially attractive aspects of this molecule, in light of the
THI/TH2 story, is that its inhibits THI but spares TH2 cytokines
[168]. Could you comment on what impact you think this molecule
will have on the treatment of acute rejection?
DR. SUTHANTFHRAN: It is an interesting idea to target the
CD28!B7 pathway with CTLA4Ig for the treatment of rejection.
In the experimental models, CTLA4Ig was administered very
early in the transplantation period to prevent rather than treat
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rejection. Because the CD28 co-stimulatory signal can function as
an amplification signal, blocking of the CD28/B7 system might be
an effective approach for the treatment of rejection. It is my belief,
however, that several molecules, rather than a single cell-surface
protein, need to be targeted in the clinic. That CD28 knockout
mice reject skin allografts as efficiently as do the wild type is in
accord with the hypothesis that several co-stimulatory pathways
rather than one single pathway need to be blocked for accom-
plishing effective immunoregulation in humans [182].
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